US pauses distribution of GSK/Vir's Covid mAb not due to Omicron, but greater supply of Eli Lilly mAbs
The US government is shifting its distribution of mAb infusions to fight the coronavirus, deciding to go from supplying tens of thousands of doses of GlaxoSmithKline and Vir’s mAb treatment sotrovimab in recent months to zero doses for the entire month of December.
That halt has led to speculation the government was prioritizing the distribution of Regeneron mAb combo of casirivimab and imdevimab and Eli Lilly’s combo of bamlanivimab and etesevimab because both companies have indicated that their infusions might not work as well against the Omicron variant (when compared to Delta).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.